Last updated: May 26, 2026
NAKION (phytomenadione, vitamin K1) clinical trials update and market projection
KONAKION is a vitamin K1 product used to treat vitamin K deficiency and prevent or treat bleeding, including in settings such as anticoagulant-associated bleeding. A current, drug-level “clinical trials update” requires up-to-date trial registry reads, and a credible market projection requires recent commercial baselines (global sales by formulation and geography) plus payer/regulatory drivers. No such source-backed inputs are provided here, so a complete and accurate update cannot be produced.
What is KONAKION (phytomenadione) used for, and what clinical trial programs exist?
KONAKION is the brand for phytomenadione (vitamin K1). The therapeutic use cases typically include:
- Prevention and treatment of bleeding due to vitamin K deficiency
- Management of bleeding related to vitamin K antagonist anticoagulation
- Neonatal indications in many countries for prophylaxis (formulation and authorization depend on jurisdiction)
What trial types would KONAKION usually generate evidence for?
- Pharmacokinetics/bioavailability studies versus comparator vitamin K1 products
- Safety and efficacy studies focused on correction of vitamin K deficiency and bleeding outcomes
- Dosing studies by route (oral vs injectable) and by population risk profile (neonates, anticoagulated patients)
What would count as “current trials update” for a vitamin K1 brand?
A proper update would require current registry coverage (e.g., ClinicalTrials.gov/EU CTR), including trial status, enrollment, endpoints, locations, and sponsors.
When do KONAKION trials report results, and what are the latest enrollment or completion timelines?
A timeline requires specific trial records (start/completion dates, posted results, publications). None are supplied.
What is the current market size for KONAKION, and how fast is it growing?
A market analysis requires at least:
- Latest annual sales by geography and formulation (oral vs injectable; concentration-specific SKUs)
- Segmentation by indication where possible (neonatal prophylaxis vs anticoagulant bleeding reversal vs deficiency states)
- Volume drivers (birth rates, anticoagulant prescribing mix, guideline changes) and switching risks (generic penetration, compendial substitution, hospital formularies)
No sales baseline, brand revenue, or official market statistics are provided.
How does KONAKION compare with vitamin K1 competitors and generics by formulation and dosing?
A competitive comparison requires product-level inputs:
- Authorized generic/brand competitors in each major market
- Injectable presentation concentration, vial format, and route approvals
- Oral strengths and capsule/tablet availability
- Tender and hospital formulary status
No competitor list or jurisdictional product mapping is provided.
What generic entry risks exist for KONAKION, and what patent or exclusivity barriers matter?
A generic entry risk assessment requires:
- Orange Book listings (US) for KONAKION and related NDA/ANDA numbers
- Patent terms, listed formulation patents, method-of-use patents, and any regulatory exclusivities (NE, 5-year, 7-year where applicable)
- Any known Paragraph IV challenges, exclusivity-triggering settlements, and FDA labeling constraints
No regulatory listing data is provided.
What is the Orange Book status of KONAKION in the US?
Orange Book status depends on the NDA/ANDA identifiers and the exact brand presentations. No Orange Book entry identifiers are supplied.
Which companies are challenging KONAKION, and what patent litigation affects timing?
A litigation update requires case captions, court, dockets, and filing/settlement dates linked to specific patents. No litigation data is provided.
How does KONAKION supply manufacturing and IP risk affect commercialization?
A manufacturing/IP barrier analysis requires:
- Contract manufacturing footprint
- Sterile manufacturing capacity for injectable versions
- Known drug shortages history by SKU
- Regulatory inspection outcomes tied to specific facilities
No facility or shortage data is provided.
What does a forecast model for KONAKION require, and what outcomes are most sensitive?
A forecast for a legacy vitamin brand is sensitive to:
- Generic substitution rates and tender dynamics in hospitals
- Changes in anticoagulant prescribing (warfarin vs DOAC mix impacts vitamin K antagonist bleeding management volume)
- Neonatal prophylaxis guideline adherence and uptake by institution
- Availability disruptions and supply continuity for injectable formulations
- Label expansion or restrictions by jurisdiction
No input variables or baseline forecast assumptions are provided.
Key Takeaways
- A “clinical trials update” and “market analysis and projection” for KONAKION requires current, source-backed trial registry and commercial data.
- No such data is provided here, so a complete and accurate, decision-grade update cannot be generated.
FAQs
- What clinical endpoints are typically used to evaluate vitamin K1 products like KONAKION in deficiency and bleeding indications?
- How do oral vs injectable phytomenadione formulations differ in pharmacokinetic and safety evidence?
- What payer and hospital formulary drivers influence vitamin K1 brand-to-generic switching in the US and Europe?
- How does changing anticoagulant prescribing mix (warfarin vs DOACs) impact demand for vitamin K1 bleeding reversal?
- What regulatory exclusivities and listed patents commonly affect generic timing for legacy small-molecule vitamin therapies?
References (APA)
No sources cited because no source-backed trial registry or market/regulatory data was provided in the request.
